Maarsingh Harm, Zaagsma Johan, Meurs Herman
Department of Molecular Pharmacology, University Centre for Pharmacy, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Eur J Pharmacol. 2008 May 13;585(2-3):375-84. doi: 10.1016/j.ejphar.2008.02.096. Epub 2008 Mar 18.
Allergic asthma is a chronic disease characterized by early and late asthmatic reactions, airway hyperresponsiveness, airway inflammation and airway remodelling. Changes in l-arginine homeostasis may contribute to all these features of asthma by decreased nitric oxide (NO) production and increased formation of peroxynitrite, polyamines and l-proline. Intracellular l-arginine levels are regulated by at least three distinct mechanisms: (i) cellular uptake by cationic amino acid (CAT) transporters, (ii) metabolism by NO-synthase (NOS) and arginase, and (iii) recycling from l-citrulline. Ex vivo studies using animal models of allergic asthma have indicated that attenuated l-arginine bioavailability to NOS causes deficiency of bronchodilating NO and increased production of procontractile peroxynitrite, which importantly contribute to allergen-induced airway hyperresponsiveness after the early and late asthmatic reaction, respectively. Decreased cellular uptake of l-arginine, due to (eosinophil-derived) polycations inhibiting CATs, as well as increased consumption by increased arginase activity are major causes of substrate limitation to NOS. Increasing substrate availability to NOS by administration of l-arginine, l-citrulline, the polycation scavenger heparin, or an arginase inhibitor alleviates allergen-induced airway hyperresponsiveness by restoring the production of bronchodilating NO. In addition, reduced l-arginine levels may contribute to the airway inflammation associated with the development of airway hyperresponsiveness, which similarly may involve decreased NO synthesis and increased peroxynitrite formation. Increased arginase activity could also contribute to airway remodelling and persistent airway hyperresponsiveness in chronic asthma via increased synthesis of l-ornithine, the precursor of polyamines and l-proline. Drugs that increase the bioavailability of l-arginine in the airways - particularly arginase inhibitors - may have therapeutic potential in allergic asthma.
过敏性哮喘是一种慢性疾病,其特征为早期和晚期哮喘反应、气道高反应性、气道炎症和气道重塑。L-精氨酸稳态的改变可能通过一氧化氮(NO)生成减少以及过氧亚硝酸盐、多胺和L-脯氨酸生成增加,导致哮喘的所有这些特征。细胞内L-精氨酸水平至少受三种不同机制调节:(i)通过阳离子氨基酸(CAT)转运体进行细胞摄取;(ii)通过一氧化氮合酶(NOS)和精氨酸酶进行代谢;(iii)从L-瓜氨酸循环利用。使用过敏性哮喘动物模型的体外研究表明,NOS的L-精氨酸生物利用度降低会导致支气管舒张性NO缺乏,并增加促收缩性过氧亚硝酸盐的生成,这分别在早期和晚期哮喘反应后对变应原诱导的气道高反应性起重要作用。由于(嗜酸性粒细胞衍生的)多阳离子抑制CATs导致L-精氨酸的细胞摄取减少,以及精氨酸酶活性增加导致消耗增加,是NOS底物限制的主要原因。通过给予L-精氨酸、L-瓜氨酸、多阳离子清除剂肝素或精氨酸酶抑制剂来增加NOS的底物可用性,可通过恢复支气管舒张性NO的生成来减轻变应原诱导的气道高反应性。此外,L-精氨酸水平降低可能导致与气道高反应性发展相关的气道炎症,这同样可能涉及NO合成减少和过氧亚硝酸盐生成增加。精氨酸酶活性增加还可能通过增加多胺和L-脯氨酸的前体L-鸟氨酸的合成,导致慢性哮喘中的气道重塑和持续性气道高反应性。增加气道中L-精氨酸生物利用度的药物——尤其是精氨酸酶抑制剂——可能在过敏性哮喘中具有治疗潜力。